Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine

TRUTAKNA met all efficacy and safety endpoints in IgAN, with FDA approval targeted for 2027.

What the company is saying

Vera Therapeutics is highlighting the final efficacy and safety results from the ORIGIN 3 trial of TRUTAKNA in adults with primary IgA nephropathy, emphasizing that all prespecified endpoints were met with statistically significant results. The company stresses that TRUTAKNA was well tolerated, with adverse events (75%) and infection rates (51.4%) comparable to placebo (78% and 52.3%, respectively), and a lower rate of serious adverse events (7% vs 15%). The narrative is framed as a transformative advance for IgAN patients, with CEO Marshall Fordyce and Professor Jonathan Barratt both quoted to underscore the clinical and patient impact. Vera is positioning TRUTAKNA as a potential disease-modifying therapy, citing its dual BAFF and APRIL inhibition mechanism. The company plans to submit a supplemental BLA in Q4 2026 and is targeting potential FDA full approval in 2027. The announcement also promotes patient access initiatives, including a copay assistance program with out-of-pocket costs as low as $0 for eligible patients. The tone is confident and forward-looking, focusing on both clinical achievement and anticipated regulatory milestones.

What the data suggests

The ORIGIN 3 trial met its primary endpoint, demonstrating statistically significant proteinuria reduction at 36 weeks, and achieved significance in all prespecified endpoints including reductions in urine-protein to creatinine ratio, galactose-deficient IgA1, and hematuria. Adverse events were reported in 160 of 214 patients (75%) on TRUTAKNA and 167 of 214 (78%) on placebo, with serious adverse events at 7% for TRUTAKNA and 15% for placebo. Infection rates were nearly identical between groups (51.4% TRUTAKNA, 52.3% placebo), and no clinically relevant hypogammaglobulinemia or opportunistic infections were observed. There was one death in the placebo group and none in the TRUTAKNA group. The most common adverse reactions (≥5%) were infections (32% TRUTAKNA vs 28% placebo) and local administration reactions (30% TRUTAKNA vs 5% placebo), with upper respiratory tract infection (12% vs 9%) and injection site reactions (19% vs 2%) being most frequent. Eligible commercially insured patients may pay as little as $0 out of pocket. At least 50% of IgAN patients may progress to kidney failure or death within 10–20 years of diagnosis, underscoring the unmet need. The data package is robust for efficacy and safety, but no commercial uptake, revenue, or cost data are disclosed.

Analysis

The announcement presents robust, well-supported clinical trial results for TRUTAKNA, including statistically significant efficacy and detailed safety data, all of which are realised and verifiable. However, the narrative is somewhat inflated by forward-looking statements about TRUTAKNA's potential to 'transform the treatment landscape' and 'change conversations,' which are not yet realised and depend on future regulatory approval. The company plans to submit a supplemental BLA in late 2026 and anticipates potential FDA full approval in 2027, placing the commercial impact in the near-term but not immediate. There is no disclosure of financial metrics (revenue, profit, cash flow), so the sustainability and commercial value of these results cannot be assessed. While the clinical data is strong, the announcement overstates the immediate impact by implying transformative change before full approval and commercial uptake. The absence of a large capital outlay or acquisition means capital intensity is not a concern here.

Risk flags

• ●Regulatory risk remains significant, as continued approval of TRUTAKNA is contingent upon verification and description of clinical benefit in a confirmatory trial. FDA full approval is not expected until 2027, and any delay or negative outcome could materially impact commercial prospects.
• ●Commercial uptake and payer coverage are unproven, with no data disclosed on actual patient access, uptake, or revenue. While the copay assistance program advertises $0 out-of-pocket for eligible patients, the financial impact and sustainability of this program are not quantified.
• ●Long-term safety and efficacy in real-world settings are untested beyond the trial period. The announcement notes that it has not been established whether TRUTAKNA slows kidney function decline over the long-term, and continued approval may depend on future confirmatory data.
• ●Competition and market dynamics are not addressed. The release does not discuss how TRUTAKNA compares to other therapies in development or on the market, which could affect future adoption and pricing power.

Bottom line

Vera Therapeutics has delivered strong final efficacy and safety data for TRUTAKNA in IgAN, positioning the drug for a supplemental BLA submission in late 2026 and aiming for FDA full approval in 2027. The clinical data are robust, with all endpoints met and a safety profile comparable to placebo, but the announcement does not provide any commercial metrics, revenue projections, or real-world uptake data. Investors should recognize that while the clinical and regulatory progress is substantial, the path to commercial value realization still depends on regulatory approval, payer coverage, and market adoption. The company’s messaging is confident and forward-looking, but the absence of financial detail means the investment case remains tied to future milestones. The most important takeaway is that TRUTAKNA is on track for a pivotal regulatory decision in 2027, with strong clinical support but commercial outcomes yet to be demonstrated.

Announcement summary

(NASDAQ:VERA) Vera Therapeutics, Inc. announced that the final efficacy analysis for the ORIGIN 3 trial of TRUTAKNA in adults with primary IgA nephropathy (IgAN) at risk for disease progression was presented at the American Society of Nephrology Kidney Week 2026 and published in The New England Journal of Medicine. The ORIGIN 3 trial met its primary endpoint, demonstrating statistically significant proteinuria reduction at 36 weeks. TRUTAKNA achieved statistical significance in all prespecified endpoints, including reductions in urine-protein to creatinine ratio, galactose-deficient IgA1, and hematuria. TRUTAKNA was well tolerated, with a safety profile generally comparable to placebo. Adverse events occurred in 160 out of 214 patients (75%) on TRUTAKNA and 167 out of 214 (78%) on placebo. The rate of serious adverse events was 7% in the TRUTAKNA group and 15% in the placebo group. Infection rates were similar between TRUTAKNA (51.4%) and placebo (52.3%) groups. There was one death in the placebo group and no deaths in the TRUTAKNA group. No clinically meaningful effect of anti-drug antibodies on efficacy or overall safety was identified. Infections were reported in 32% of TRUTAKNA patients compared with 28% of placebo patients. The most common adverse reactions (≥5%) were infections (32% TRUTAKNA vs 28% placebo) and local administration reactions (30% TRUTAKNA vs 5% placebo). The most common infection was upper respiratory tract infection (12% TRUTAKNA vs 9% placebo). The most common local administration reactions were injection site reaction (19% TRUTAKNA vs 2% placebo) and injection site erythema (6% TRUTAKNA vs 1% placebo). Eligible commercially insured patients may pay as little as $0 out of pocket through the TRUTAKNA copay assistance program. At least 50% of IgAN patients may progress to kidney failure or death within 10 to 20 years of diagnosis. Vera Therapeutics plans to submit the supplemental BLA in the fourth quarter of 2026 and anticipates potential FDA full approval of TRUTAKNA in 2027. TRUTAKNA is indicated to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression, approved under accelerated approval based on reduction of proteinuria. Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. TRUTAKNA is self-administered as a 1 ml, 150 mg once-weekly autoinjector. Vera Therapeutics will host an investor call and webcast to discuss the trial results at 4:30 PM EST on October 22, 2026.

Disagree with this article?